The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 16, 2024

Filed:

Apr. 06, 2021
Applicant:

Marshall University Research Corporation, Huntington, WV (US);

Inventors:

Juan Sanabria, Huntington, WV (US);

Sandrine Pierre, Huntington, WV (US);

Moumita Banerjee, Huntington, WV (US);

Zijian Xie, Huntington, WV (US);

Joseph Shapiro, Huntington, WV (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/08 (2006.01); A61K 38/00 (2006.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 7/08 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57438 (2013.01); G01N 33/6848 (2013.01); A61K 38/00 (2013.01); C07K 2319/10 (2013.01); G01N 2333/4703 (2013.01); G01N 2800/52 (2013.01);
Abstract

Methods for treating non-alcoholic steatohepatitis and/or hepatocellular carcinoma include administering a polypeptide antagonist of a Na/K ATPase/Src receptor complex to a subject in need thereof. Methods and assays for diagnosis or prognosis of non-alcoholic steatohepatitis and/or hepatocellular carcinoma in a subject are also provided and include the steps of providing a biological sample from the subject, determining an expression level or activity in the sample of at least one biomarker selected from Caveolin-1, Survivin, and SMAC; and comparing the expression level or activity of the at least one biomarker in the sample, if present, to a control expression level or activity of the at least one biomarker. Prophylaxis or treatment of the non-alcoholic steatohepatitis and/or hepatocellular carcinoma in a subject can then be initiated based on the expression level or activity of Caveolin-1, Survivin, and SMAC in the sample.


Find Patent Forward Citations

Loading…